Penetration of the blood-brain barrier and anti-tumor effect of a novel PLGA-lysoGM1/DOX micelles drug delivery system
Effective treatment of glioma and other central nervous system (CNS) diseases is hindered by the presence of the blood-brain barrier (BBB). A novel nano-delivery vehicle system comprised of PLGA-lysoGM1/DOX micelles was developed to across the BBB for CNS administration. We have shown that Doxorubicin (DOX) as a model drug encapsulated in PLGA-lysoGM1 micelles, can achieve up to 3.8% loading efficiency and 61.6% encapsulation efficiency by the orthogonal test design. Our in vitro experiments demonstrate that PLGA-lysoGM1/DOX micelles have a slow and sustainable drug release under physiological conditions and exhibit a high cellular uptake through the macropinocytosis and the autophagy/lysosomal pathways. In vivo experimental studies in zebrafish and mice confirmed that PLGA-lysoGM1/DOX micelles could across the BBB and specifically accumulated in the brain. Moreover, an excellent anti-glioma effect presented in intracranial glioma‐bearing rat. Therefore, PLGA-lysoGM1/DOX micelles not only effectively acrossed the BBB, but our results suggest it has a great potential for anti-glioma therapy and other central nervous system diseases.
- This article is part of the themed collection: 2020 Nanoscale HOT Article Collection